Share Price:

APNASPENAspen Pharmacare Hldgs2405395 (0.40%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Pharmacovigilance

Team Overview

The Group Pharmacovigilance team, supported by the local business units, is responsible for monitoring and managing the safety of all our products globally. Pharmacovigilance covers the activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems and is core to our patient responsibility.

Working At Aspen

We believe that doing business in a sustainable and responsible manner is integral to our purpose, our values and our philosophy “Healthcare. We Care”.


Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business.

 

Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business.

Innovation

We constantly search for better ways of doing things

Excellence

We strive to be the best we can be to deliver the highest standards

Commitment

We go the extra mile, seeking to exceed expectations

Teamwork

We optimise our performance by pulling together

Integrity

Our integrity is not negotiable

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.